![Jeffrey Greve](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Jeffrey Greve is the founder of Delinia, Inc. (founded in 2015) and Kyverna Therapeutics, Inc. (founded in 2018).
At Delinia, he held the title of Chief Scientific Officer.
At Kyverna Therapeutics, he held the title of Chief Scientific Officer from 2018 to 2022.
Dr. Greve's former job was as Vice President-Research at aTyr Pharma, Inc. Dr. Greve earned a doctorate degree from the University of Washington and an undergraduate degree from The Johns Hopkins University.
Anciens postes connus de Jeffrey Greve
Sociétés | Poste | Fin |
---|---|---|
KYVERNA THERAPEUTICS, INC. | Fondateur | 23/08/2022 |
Delinea, Inc. (United States)
![]() Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Fondateur | - |
ATYR PHARMA, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Jeffrey Greve
University of Washington | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ATYR PHARMA, INC. | Health Technology |
KYVERNA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Delinea, Inc. (United States)
![]() Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |